<code id='30B19A1BB7'></code><style id='30B19A1BB7'></style>
    • <acronym id='30B19A1BB7'></acronym>
      <center id='30B19A1BB7'><center id='30B19A1BB7'><tfoot id='30B19A1BB7'></tfoot></center><abbr id='30B19A1BB7'><dir id='30B19A1BB7'><tfoot id='30B19A1BB7'></tfoot><noframes id='30B19A1BB7'>

    • <optgroup id='30B19A1BB7'><strike id='30B19A1BB7'><sup id='30B19A1BB7'></sup></strike><code id='30B19A1BB7'></code></optgroup>
        1. <b id='30B19A1BB7'><label id='30B19A1BB7'><select id='30B19A1BB7'><dt id='30B19A1BB7'><span id='30B19A1BB7'></span></dt></select></label></b><u id='30B19A1BB7'></u>
          <i id='30B19A1BB7'><strike id='30B19A1BB7'><tt id='30B19A1BB7'><pre id='30B19A1BB7'></pre></tt></strike></i>

          focus

          focus

          author:focus    Page View:79984
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          Morphosys mixed study results for blood cancer drug
          Morphosys mixed study results for blood cancer drug

          AdobeLONDON—AnexperimentalbloodcancerdrugfromMorphoSyshititsprimarytargetinapivotaltrial,thecompanya

          read more
          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more

          Readout LOUD podcast: ALS dilemma, first MASH drug, and more

          Whathappenswhenanapproveddrugdoesn’twork?Whydon’tpatientswantgenetherapy?AndisMASHstillabigdeal?Weco